- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00376194
Mercury Chelation to Treat Autism
An Investigation of the Efficacy of Mercury Chelation as a Treatment for Autism Spectrum Disorder
This study will examine whether DMSA, an oral chelating agent that removes mercury and other metals from the body, is beneficial for children with autism. DMSA is commonly used to treat autism, although it has never been tested in a controlled study and there is no proof that it helps children with the disorder. Support for its use is based on single-case reports of benefits of chelation with DMSA. This study will help determine whether or not DMSA is useful for treating autism.
Children between 4 and 10 years of age with autism spectrum disorder who weigh at least 33 pounds, who have detectable, but not toxic, levels of mercury or lead in the blood, and who have not previously received chelation therapy may be eligible for this study.
Participants complete a medical history, behavioral and psychological assessment and physical examination. Blood, hair, urine and stool samples are collected for testing.
Because DMSA can remove minerals the body needs, such as zinc and iron, as well as the toxic lead and mercury, participants take a daily multivitamin supplement starting 1 month before beginning chelation therapy and continuing for the duration of treatment. After 1 month of the supplementation regimen, the children are assigned to receive DMSA or placebo for 12 weeks, divided into six 2-week cycles. They take the assigned drug 3 times a day on days 1, 2 and 3 of each cycle and continue the multivitamin every day.
The children are seen in the clinic immediately before and after the first, third and sixth cycles. At each checkup, the parent or guardian answers a set of questions about the child's autism symptoms, physical health and medication side effects. Blood, urine and stool samples are collected for laboratory testing.
...
Study Overview
Status
Intervention / Treatment
Detailed Description
Chelation of metals is widely used in the community to treat individuals with Autism Spectrum Disorder (ASD), with some surveys estimating that 1 in 12 children with autism have undergone chelation. This widespread use reflects the hypothesis that many cases of ASD are caused by exposure to thimerosal, an ethylmercury-based compound used previously in the US as a vaccine preservative for routine childhood immunizations. The prevalent use of chelation therapy stands in stark contrast with the lack of scientific or clinical evidence of efficacy, and creates a public health imperative for empiric data. Thus we propose a controlled trial of the effects of chelation on the core behavioral symptoms and overall functioning of children with ASD. The present investigation is a double-blind, randomized placebo-controlled study of the oral chelating agent meso-2,3-dimercaptosuccinic acid (DMSA; succimer) among 120 children, ages four to ten years, who meet criteria for ASD. Pre- and post-treatment behavioral ratings will be used to evaluate the efficacy of chelation. In addition, children will undergo comprehensive medical history, physical examination and laboratory analyses.
Our objective is to quantify differences in behavioral functioning between the chelation treatment group and the placebo control group. Analysis of mercury levels before and during the course of treatment will be used to confirm the expected DMSA-induced excretion of mercury and to identify differences among children in the extent of excretion. Our primary hypothesis is that, on average and relative to the control group, children with ASD who undergo chelation with DMSA will show greater improvements in communication and social behavior.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institute of Mental Health (NIMH), 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Subjects may be included in the study only if they meet all of the following criteria:
- Male or female subjects, four to ten years of age.
- Meets research criteria for ASD (specifically, autism, Asperger Disorder, or Pervasive Developmental Disorder - Not Otherwise Specified).
- Detectable (greater than 0.1 microgram per deciliter) levels of blood lead and/or blood mercury.
- Each legal guardian must have a level of understanding sufficient to agree to all required tests and examinations. Each legal guardian must understand the nature of the study and must provide written consent to study protocol.
EXCLUSION CRITERIA:
- History of allergic reaction to sulfur or thiol-containing substances
- History of previous chelation therapy for autism
- History of uncontrolled epilepsy
- Weight less than 15 kg at screening
- Presence of a chronic medical condition that might interfere with study participation in which study participation would be contraindicated or in which there may be clinically significant abnormal baseline laboratory results.
- Level of lead above 10 microgram per d, or level of mercury over 44 microgram per deciliter (toxic levels that require intervention with chelation and preclude placebo assignment) or other evidence of heavy metal toxicity.
- Recent (less than two months prior to study entry) initiation of behavior therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Improvement in social reciprocity.
|
Secondary Outcome Measures
Outcome Measure |
---|
Improvement in language skills, decrease in blood mercury levels.
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Aposhian HV, Aposhian MM. meso-2,3-Dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharmacol Toxicol. 1990;30:279-306. doi: 10.1146/annurev.pa.30.040190.001431.
- Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses. 2001 Apr;56(4):462-71. doi: 10.1054/mehy.2000.1281.
- Chisolm JJ Jr. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. J Toxicol Clin Toxicol. 2000;38(4):365-75. doi: 10.1081/clt-100100945.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 060238
- 06-M-0238
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Child Development Disorders, Pervasive
-
Eunice Kennedy Shriver National Institute of Child...Yale UniversityTerminatedAutism | Pervasive Child Development DisordersUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH); University of Pittsburgh; Emory University and other collaboratorsCompletedChild Development Disorders, PervasiveUnited States
-
Rabin Medical CenterTerminatedChild Development Disorders, PervasiveIsrael
-
McGill University Health Centre/Research Institute...Canadian Institutes of Health Research (CIHR); University of AlbertaActive, not recruitingParent-Child Relations | Autism Spectrum Disorder | Parenting | Mental Health Wellness 1 | Parent-child Problem | Child Development Disorder | Child Developmental DelayCanada
-
Stanford UniversityJohn & Marcia Goldman FoundationRecruitingAutism Spectrum Disorder | Developmental Disability | Development Delay | Development Disorder, ChildUnited States
-
Ataturk UniversityPhd Nurgül KarakurtCompletedChild Development Disorders, Pervasive | Mother-Infant Interaction | Problems PsychosocialTurkey
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Hoffmann-La RocheCompletedMental Disorders | Neurodevelopmental Disorders | Autism Spectrum Disorder | Autistic Disorder | Child Development Disorders, PervasiveUnited Kingdom
-
Virginia Polytechnic Institute and State UniversityNational Institute of Mental Health (NIMH)CompletedAutistic Disorder | Child Development Disorders, PervasiveUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedAutism Spectrum Disorder | Autistic Disorder | Child Development Disorders, Pervasive | Autism | Asperger Syndrome | Pervasive Developmental DisorderUnited States
Clinical Trials on DMSA
-
Assiut UniversityUnknownHypertension | Diabetes MellitusEgypt
-
Sohag UniversityNot yet recruitingPatients Referred for Renal DMSA ScintigraphyEgypt
-
Göteborg UniversityCompleted
-
Assiut UniversityUnknownThe Difference in Estimation of Split Renal Function Using the Two Radiopharmaceuticals:Tc-99m DTPA & Tc-99m DMSA in Kidney Patients
-
Assiut UniversityNot yet recruiting
-
Southwest College of Naturopathic MedicineCompleted
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome and other conditionsUnited States
-
Royal Marsden NHS Foundation TrustCompletedExposure to Medical Diagnostic RadiationUnited Kingdom